Carbetocin Peptide: Long-Acting Oxytocin Analog for Postpartum Hemorrhage
Carbetocin peptide guide covering its oxytocin-receptor mechanism, Duratocin and heat-stable formulations, CHAMPION trial evidence, dosing context and safety limits.
Carbetocin is a peptide medicine with a very different evidence profile from research-market wellness peptides. It is a synthetic, long-acting analog of the natural hormone oxytocin, used in prescription products such as Duratocin, Pabal and Lonactene to prevent excessive bleeding after childbirth.
The key context is obstetric. Carbetocin is a uterotonic, meaning it makes the uterus contract. It is given by clinicians immediately after delivery to reduce the risk of postpartum hemorrhage, the leading cause of maternal death worldwide. It is not a fertility peptide, a bonding or mood peptide, or a general "oxytocin booster," even though it acts on the same receptor as oxytocin.
This guide is educational and not medical advice. Carbetocin is a prescription medicine administered in supervised clinical settings. It should only be used under qualified medical care.
Carbetocin At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A synthetic long-acting octapeptide analog of oxytocin. |
| Common brands | Duratocin, Pabal, Lonactene, plus a heat-stable formulation. |
| Main effect | Sustained uterine contraction to reduce postpartum bleeding. |
| Receptor target | Peripheral oxytocin receptors, mainly in the myometrium. |
| Main clinical use | Prevention of uterine atony and postpartum hemorrhage after cesarean or vaginal birth. |
| Evidence type | Product labels, randomized trials, Cochrane network meta-analysis and WHO review. |
| Regulatory status | Approved in many countries; WHO-listed heat-stable version; not FDA approved in the US. |
How Carbetocin Works
Oxytocin is released naturally from the posterior pituitary and binds oxytocin receptors in the smooth muscle of the uterus, triggering rhythmic contractions. After delivery, strong sustained uterine contraction compresses the blood vessels that supplied the placenta. When the uterus fails to contract, a state called uterine atony, those vessels keep bleeding, which is the most common cause of postpartum hemorrhage.
Carbetocin is engineered to do the same job for longer. According to the Ferring Duratocin product monograph and pharmacology reviews, it acts as an agonist at peripheral oxytocin receptors, particularly in the myometrium, producing contractions that begin within about two minutes of injection.
The difference is durability. Natural and synthetic oxytocin are broken down quickly, with a reported half-life near 3.5 minutes, so clinicians often give oxytocin as a continuous intravenous infusion over hours. Carbetocin's structure resists that rapid breakdown. It is a deaminated analog in which the disulfide bridge of oxytocin is replaced by a more stable thioether linkage, alongside a modified tyrosine residue. The reported elimination half-life is roughly 85 to 100 minutes, allowing a single injection to maintain uterine tone for an hour or more. If you want the general concept behind these numbers, see the peptide half-life guide.
A Heat-Stable Formulation
A major practical limitation of oxytocin is that it requires refrigeration. In hot, low-resource settings, oxytocin can degrade and lose potency before it reaches the women who need it. A room-temperature-stable formulation of carbetocin was developed through a collaboration involving Ferring Pharmaceuticals, MSD for Mothers and the World Health Organization, specifically to address this cold-chain problem.
Heat-stable carbetocin can be stored at higher temperatures and humidity without the same loss of quality, which is why it is included on the WHO Model List of Essential Medicines. This logistical advantage, not a difference in receptor biology, is the central reason the heat-stable version attracted global public health attention.
What The Evidence Shows
Carbetocin has a substantial clinical evidence base for postpartum hemorrhage prevention, which separates it sharply from unapproved peptides.
The landmark study is the WHO-led CHAMPION trial, published in the New England Journal of Medicine in 2018. It was a double-blind, randomized, non-inferiority trial that enrolled roughly 29,600 women across 23 hospitals in 10 countries. Women delivering vaginally received a single intramuscular injection of either 100 micrograms of heat-stable carbetocin or 10 international units of oxytocin immediately after birth. The trial reported that blood loss of at least 1000 mL occurred in 1.51% of the carbetocin group and 1.45% of the oxytocin group, meeting the pre-specified definition of non-inferiority for that outcome.
It is important to read that result precisely. CHAMPION showed carbetocin was non-inferior to oxytocin for the 1000 mL outcome, but the trial did not establish non-inferiority for the separate outcome of blood loss of at least 500 mL. In other words, the headline is "comparable to oxytocin," not "clearly superior."
Broader synthesis supports a roughly similar standing. A 2018 Cochrane network meta-analysis of uterotonic agents found that carbetocin may reduce the need for additional uterotonic drugs compared with oxytocin, particularly after cesarean delivery, but the authors graded much of the underlying evidence cautiously. The WHO recommendation on uterotonics likewise positions heat-stable carbetocin as an effective option while still listing oxytocin as a primary choice.
The honest summary is that carbetocin is a legitimate, label-approved uterotonic with large randomized evidence, while the magnitude of any advantage over oxytocin remains modest and context-dependent.
Dosing Context, Not A Recommendation
The following figures describe what appears in product labels and trials. They are not dosing advice, and carbetocin is only given by clinicians.
According to the Ferring Duratocin label, the product is administered as a single 100 microgram dose. For cesarean section, the label describes slow intravenous injection over about one minute once the baby is delivered. In the CHAMPION trial and the heat-stable vaginal-birth setting, the same 100 microgram dose was given as a single intramuscular injection. A defining feature of carbetocin is that, unlike oxytocin, it is designed as a one-time dose rather than a prolonged infusion.
Safety Limits
Carbetocin's safety profile overlaps with oxytocin, since both act on the same receptor. Labels and a 2021 systematic review of randomized trials describe the main issues.
| Safety issue | Why it matters |
|---|---|
| Cardiovascular contraindication | Labels advise against use in patients with serious cardiovascular disease; oxytocin-receptor agonists can affect blood pressure and heart rate. |
| Hypotension and flushing | Transient drops in blood pressure, flushing and tachycardia are reported, particularly with rapid intravenous administration. |
| Gastrointestinal effects | Nausea, vomiting and abdominal pain are among the more common reported reactions. |
| Headache and tremor | Headache, dizziness and tremor appear in label adverse-event lists. |
| Timing restriction | It is intended for use after delivery of the infant, not to induce or augment labor; antepartum use is contraindicated. |
| Preeclampsia and eclampsia caution | Labels and reviews advise caution given cardiovascular and seizure-threshold concerns. |
| Water retention risk | As an oxytocin analog, large or repeated exposure raises theoretical concern for fluid retention, though single-dose use limits this. |
The 2021 meta-analysis concluded that carbetocin's overall side-effect burden is broadly comparable to oxytocin, without a clear increase in serious harms in the postpartum prevention setting. As always, the label and clinical judgment govern actual use.
The Prader-Willi Detour: A Lesson In Reading Claims
Carbetocin has been studied beyond obstetrics, and that history is a useful caution. An intranasal carbetocin product, developed as LV-101 by Levo Therapeutics, was investigated for hyperphagia, the relentless hunger associated with Prader-Willi syndrome. Despite the program reaching late-stage trials and FDA review, it did not secure FDA approval for that indication.
This matters for evaluating any carbetocin claim. The fact that a peptide is approved for one tightly defined use, postpartum hemorrhage prevention, does not mean it is proven for behavioral, metabolic or "oxytocin-system" uses. The same discipline applies when comparing carbetocin to other clinically approved peptides that are sometimes lumped together online, such as octreotide, linaclotide, teduglutide and icatibant. Each has its own narrow, label-defined indication. None of them, and not carbetocin, should be treated as interchangeable wellness tools. For the broader framing, see what peptides are.
How To Evaluate A Carbetocin Claim
Ask five questions.
First, is the claim about postpartum hemorrhage prevention, the actual approved use, or about something else like mood, bonding, appetite or anti-aging? Only the first has label backing.
Second, does the source distinguish the standard formulation from the heat-stable one? They share biology but differ in storage and global-health role.
Third, does it acknowledge that CHAMPION showed non-inferiority to oxytocin, not clear superiority?
Fourth, does it mention that carbetocin is a clinician-administered, single-dose injection given after delivery, not a self-administered product?
Fifth, is it implying FDA approval or unsupervised human use? Carbetocin is not FDA approved in the United States, and any vendor selling it for self-use is a red flag.
Bottom Line
Carbetocin is a real, approved peptide medicine with a clear and important job: preventing postpartum hemorrhage by sustaining uterine contraction after birth. Its long-acting design and heat-stable formulation are genuine advances, supported by the large CHAMPION trial, Cochrane analysis and WHO listing.
The same evidence defines its limits. Carbetocin is non-inferior to oxytocin rather than dramatically better, it is a single-dose drug given by clinicians in a specific obstetric window, and it is not FDA approved in the United States. Its failed intranasal program in Prader-Willi syndrome underscores that an oxytocin analog approved for one narrow indication is not a general-purpose "oxytocin" peptide. Outside the delivery room, claims about carbetocin deserve real scrutiny.
References
Widmer M, Piaggio G, Nguyen TMH, et al. Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth. New England Journal of Medicine, 2018.
Ferring Pharmaceuticals. Duratocin (carbetocin injection) Product Monograph.
Gallos ID, Williams HM, Price MJ, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database of Systematic Reviews, 2018.
World Health Organization. WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage — Choice of uterotonic agents.
Ai W, Zeng Y, Ma Y, et al. Side-effects of carbetocin to prevent postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials. Pharmacology Research & Perspectives, 2021.
Voon HY, Suharjono HN, Shafie AA, Bujang MA. Current research on carbetocin and implications for prevention of postpartum haemorrhage. Reproductive Health, 2018.
Widmer M, Piaggio G, Hofmeyr GJ, et al. Room temperature stable carbetocin for the prevention of postpartum haemorrhage: study protocol for a randomized controlled trial. Trials, 2016.
Pickering K, Gallos ID, Williams H, et al. Implementing Heat-Stable Carbetocin for Postpartum Haemorrhage Prevention in Low-Resource Settings: A Rapid Scoping Review. 2022.
Canadian Agency for Drugs and Technologies in Health. Carbetocin for the Prevention of Post-Partum Hemorrhage: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines.
Drugs.com. LV-101 (intranasal carbetocin) FDA development history for Prader-Willi syndrome.